Automated Insulin Delivery Systems to Boost CGM Market

The continuous glucose monitor (CGM) and insulin pump sector is set to skyrocket this decade, driven by the prevalence of diabetes amongst the world’s population and new technology.

GlobalData estimates the CGM and insulin pumps market value to be $10.7 billion last year and projects it to expand 7.3% annually to reach $20.2 billion in 2030. “The market is driven by the increase in the prevalence of people with diabetes and growing awareness among consumers regarding the availability of new technological advancements such as AID in the market,” said Tina Deng, MSc, a principal medical devices analyst at GlobalData. “While AID systems are primarily used in type 1 diabetes, patients with type 2 diabetes taking multiple daily injections can also benefit from this technology.”  

Patients with insulin-dependent diabetes have difficulty maintaining a healthy blood glucose level. Automated insulin delivery (AID) systems, or hybrid closed loop systems, have been developed to make maintaining a healthy glucose level easier. This has led to increased awareness among patients with insulin-dependent diabetes. 

According to GlobalData’s clinical trials database, there have been more than 60 ongoing or planned clinical trials for AID. Most of them focus on the safety and efficacy in different subpopulations, including young children, athletes, and pregnant women. Other trials test innovation in improving pipeline or marketed AID systems, such as better interoperability between different pumps and CGMs, more affordable devices, and easier general usability. 
 
“AID systems, or hybrid closed loop systems, allow for a complete circle of communication between a continuous glucose monitor (CGM) and insulin pump, which track blood glucose and automatically adjust insulin delivery to help control blood glucose levels,” Deng said. “Based on a few large, randomized, controlled outpatient studies for children and adults, recent developments in AID systems have led to improved clinical outcomes, including overall time-in-range improvement by an average of 10%, reduced frequency of diabetic ketoacidosis hospitalizations, and decrease in hypoglycemia and time-below-range.” 
 
Recently, an NIH-funded research team led by Dr. Russell at Massachusetts General Hospital developed an AID system with less user input than existing methods. The researchers tested the device in a randomized trial with more than 300 participants with type 1 diabetes in 16 clinical centers in the United States. It was found that this system could safely improve glucose control with much less input from users and their healthcare providers, making day-to-day management of type 1 diabetes easier, leading to better quality of life. 
 
“The more positive clinical outcome is expected to boost the innovation and application of AID, driving the device market to a new level in the future,” Deng concluded.